The Prevention and Treatment of Radiation and Chemotherapy-Induced Intestinal Mucositis

The Microbiota in Gastrointestinal Pathophysiology: Implications for Human Health, Prebiotics, Probiotics, and Dysbiosis

Volumn , Issue , 2017, Pages 383-387

  Ciorba, M A ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Bifidobacterium; Colon cancer; CTLA 4; Lactobacillus; PD L1; Radiotherapy

Indexed keywords

EID: 85027381855     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-804024-9.00041-0     Document Type: Chapter

References (50)

1. Paris F., Fuks Z., Kang A., et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001, 293:293-297.
2. Epstein J., Silverman S., Paggiarino D., et al. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis. Cancer 2001, 92:875-885.
3. Sonis S.T., Peterson R.L., Edwards L.J., et al. Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 2000, 36:373-381.
4. Hauer-Jensen M., Denham J.W., Andreyev H.J. Radiation enteropathy-pathogenesis, treatment and prevention. Nat Rev Gastroenterol Hepatol 2014, 11:470-479.
5. Lalla R.V., Bowen J., Barasch A., et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014, 120:1453-1461.
6. Elting L.S., Cooksley C., Chambers M., et al. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003, 98:1531-1539.
7. Trotti A., Bellm L.A., Epstein J.B., et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 2003, 66:253-262.
8. Huang K., Haas-Kogan D., Weinberg V., et al. Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. World J Gastroenterol 2007, 13:895-900.
9. Chapet O., Gerard J.P., Riche B., et al. Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer. Int J Radiat Oncol Biol Phys 2005, 63:1316-1324.
10. Packey C.D., Ciorba M.A. Microbial influences on the small intestinal response to radiation injury. Curr Opin Gastroenterol 2010, 26:88-94.
11. Crawford P.A., Gordon J.I. Microbial regulation of intestinal radiosensitivity. Proc Natl Acad Sci USA 2005, 102:13254-13259.
12. McLaughlin M.M., Dacquisto M.P., Jacobus D.P., et al. Effects of the germfree state on responses of mice to whole-body irradiation. Radiat Res 1964, 23:333-349.
13. Burdelya L.G., Krivokrysenko V.I., Tallant T.C., et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008, 320:226-230.
14. Riehl T., Cohn S., Tessner T., et al. Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-mediated mechanism. Gastroenterology 2000, 118:1106-1116.
15. Ciorba M.A., Riehl T.E., Rao M.S., et al. Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. Gut 2012, 61:829-838.
16. Montassier E., Gastinne T., Vangay P., et al. Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther 2015, 42:515-528.
17. Manichanh C., Varela E., Martinez C., et al. The gut microbiota predispose to the pathophysiology of acute postradiotherapy diarrhea. Am J Gastroenterol 2008, 103:1754-1761.
18. Williams M.D., Ha C.Y., Ciorba M.A. Probiotics as therapy in gastroenterology: a study of physician opinions and recommendations. J Clin Gastroenterol 2010, 44:631-636.
19. Sartor R.B. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008, 134:577-594.
20. Snydman D.R. The safety of probiotics. Clin Infect Dis 2008, 46(Suppl. 2):S104-S111. discussion S144-S151.
21. Ciorba M.A. A gastroenterologist's guide to probiotics. Clin Gastroenterol Hepatol 2012, 19:960-968.
22. Floch M.H., Walker W.A., Sanders M.E., et al. Recommendations for probiotic use-2015 update: proceedings and consensus opinion. J Clin Gastroenterol 2015, 49(Suppl. 1):S69-S73.
23. Mennigen R., Nolte K., Rijcken E., et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 2009, 296:G1140-G1149.
24. Madsen K., Cornish A., Soper P., et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001, 121:580-591.
25. Seth A., Yan F., Polk D.B., et al. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism. Am J Physiol Gastrointest Liver Physiol 2008, 294:G1060-G1069.
26. Yan F., Cao H., Cover T.L., et al. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007, 132:562-575.
27. Touchefeu Y., Montassier E., Nieman K., et al. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis-current evidence and potential clinical applications. Aliment Pharmacol Ther 2014, 40:409-421.
28. Ciorba M.A., Stenson W.F. Probiotic therapy in radiation-induced intestinal injury and repair. Ann NY Acad Sci 2009, 1165:190-194.
29. Ciorba M.A., Hallemeier C.L., Stenson W.F., et al. Probiotics to prevent gastrointestinal toxicity from cancer therapy: an interpretive review and call to action. Curr Opin Support Palliat Care 2015, 9:157-162.
30. Frank M., Hennenberg E.M., Eyking A., et al. TLR signaling modulates side effects of anticancer therapy in the small intestine. J Immunol 2015, 194:1983-1995.
31. Jones R.M., Sloane V.M., Wu H., et al. Flagellin administration protects gut mucosal tissue from irradiation-induced apoptosis via MKP-7 activity. Gut 2011, 60:648-657.
32. Salminen E., Elomaa I., Minkkinen J., et al. Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures. Clin Radiol 1988, 39:435-437.
33. Delia P., Sansotta G., Donato V., et al. Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol 2007, 13:912-915.
34. Delia P., Sansotta G., Donato V., et al. Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. Am J Gastroenterol 2002, 97:2150-2152.
35. Giralt J., Regadera J.P., Verges R., et al. Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial. Int J Radiat Oncol Biol Phys 2008, 71:1213-1219.
36. Chitapanarux I., Chitapanarux T., Traisathit P., et al. Randomized controlled trial of live Lactobacillus acidophilus plus Bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients. Radiat Oncol 2010, 5:31.
37. Gibson R.J., Keefe D.M., Lalla R.V., et al. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 2013, 21:313-326.
38. Demers M., Dagnault A., Desjardins J. A randomized double-blind controlled trial: impact of probiotics on diarrhea in patients treated with pelvic radiation. Clin Nutr 2014, 33:761-767.
39. Nascimento M., Aguilar-Nascimento J.E., Caporossi C., et al. Efficacy of synbiotics to reduce acute radiation proctitis symptoms and improve quality of life: a randomized, double-blind, placebo-controlled pilot trial. Int J Radiat Oncol Biol Phys 2014, 90:289-295.
40. Wedlake L., McGough C., Hackett C., et al. Can biological markers act as non-invasive, sensitive indicators of radiation-induced effects in the gastrointestinal mucosa?. Aliment Pharmacol Ther 2008, 27:980-987.
41. Jones R.M., Desai C., Darby T.M., et al. Lactobacilli modulate epithelial cytoprotection through the Nrf2 pathway. Cell Rep 2015, 12:1217-1225.
42. Ciorba MA. Probiotic LGG for prevention of side effects in patients undergoing chemoradiation for gastrointestinal cancer, 2016. https://clinicaltrials.gov/ct2/show/NCT01790035.
43. Wedlake L.J., Shaw C., Whelan K., et al. Systematic review: the efficacy of nutritional interventions to counteract acute gastrointestinal toxicity during therapeutic pelvic radiotherapy. Aliment Pharmacol Ther 2013, 37:1046-1056.
44. Scartoni D., Desideri I., Giacomelli I., et al. Nutritional supplement based on zinc, prebiotics, probiotics and vitamins to prevent radiation-related gastrointestinal disorders. Anticancer Res 2015, 35:5687-5692.
45. van Vliet M.J., Harmsen H.J., de Bont E.S., et al. The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog 2010, 6:e1000879.
46. Stringer A.M., Al-Dasooqi N., Bowen J.M., et al. Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer 2013, 21:1843-1852.
47. Yeung C.Y., Chan W.T., Jiang C.B., et al. Amelioration of chemotherapy-induced intestinal mucositis by orally administered probiotics in a mouse model. PLoS One 2015, 10:e0138746.
48. Viaud S., Saccheri F., Mignot G., et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013, 342:971-976.
49. Vetizou M., Pitt J.M., Daillere R., et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015, 350:1079-1084.
50. Sivan A., Corrales L., Hubert N., et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015, 350:1084-1089.